Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. reports developments as a pharmaceutical company with commercial generic prescription drugs in Canada and proprietary drug-development programs in oncology and antivirals. News commonly covers product launches through its Nora Pharma subsidiary, including generic medicines such as Domperidone, Doxycycline and Pravastatin, as well as Health Canada commercialization approvals and expansion of therapeutic categories.
The company’s updates also address financial results, portfolio growth and research programs including K1.1 mRNA, an mRNA-lipid nanoparticle candidate targeting liver cancer, and a PLpro protease inhibitor for SARS-related coronavirus infections. Corporate and treasury actions may appear alongside operating updates when they affect Sunshine Biopharma’s capital strategy or public-company profile.
Sunshine Biopharma (NASDAQ:SBFM) announced Canadian approval of its generic Rivaroxaban tablets in 2.5mg, 10mg, 15mg and 20mg strengths, a generic equivalent of Xarelto®.
The drug will be distributed through Nora Pharma in Canada, expands the company’s anticoagulant portfolio alongside Apixaban, and is anticipated to ship in October 2026.
Sunshine Biopharma (NASDAQ:SBFM) announced issuance of U.S. Patent 12,624,066 B2 covering proprietary small-molecule compounds for treatment of coronavirus infection. The patent protects PLpro enzyme inhibitors designed to block viral replication and immune suppression. Compounds are ready for GLP studies, the final step before entering clinical trials.
Sunshine Biopharma (NASDAQ:SBFM) approved a 1-for-10 reverse stock split of its common shares, effective at market open on June 1, 2026. The action aims to regain compliance with Nasdaq’s minimum bid price requirement and will reduce outstanding shares from 21,236,346 to approximately 2,123,635.
Sunshine Biopharma (NASDAQ:SBFM) received Canadian regulatory approval for its generic Amoxicillin, supporting its strategy in generic antibiotics. The product will be offered in multiple dosage forms and strengths and is anticipated to ship to Canadian pharmacies in August 2026.
Amoxicillin global sales were estimated at $4.9–$5.9 billion in 2025, with 2.9% CAGR projected to about $6.4 by 2031. Canada represents roughly 2% of global Amoxicillin sales.
Sunshine Biopharma (NASDAQ:SBFM) closed a public offering raising approximately $6.0 million in gross proceeds from 12,000,000 Common (or Pre-Funded) Units priced at $0.50 per Common Unit.
Each unit includes one share (or pre-funded warrant) plus two Series C Warrants, which could generate up to an additional ~$12.0 million if fully exercised.
Sunshine Biopharma (NASDAQ:SBFM) priced a reasonable best efforts public offering expected to raise approximately $6.0 million in gross proceeds. The offering includes 12,000,000 Common Units or Pre-Funded Units at $0.50 per Common Unit (or $0.49999 per Pre-Funded Unit).
Each unit consists of one share of common stock or one pre-funded warrant plus two Series C warrants with a $0.50 exercise price, exercisable immediately. Closing is expected around May 19, 2026. Net proceeds are earmarked for general corporate purposes and working capital. The SEC declared the Form S-1 registration statement effective on May 18, 2026.
Sunshine Biopharma (NASDAQ:SBFM) filed its Form 10-K for fiscal 2025, reporting $36.31 million revenue, a 4.1% increase versus 2024. Gross profit rose to $12.26 million while net loss widened to $5.98 million.
The company raised $2.46 million via a registered direct offering, launched nine new generic drugs, recorded a $1.75 million non‑cash impairment, and announced planned 2026 cost reductions of approximately $2–3 million.
Sunshine Biopharma (NASDAQ: SBFM) announced Health Canada authorization to commercialize domperidone through Nora Pharma on October 28, 2025, giving the company market access in Canada.
Key figures cited: global domperidone sales projected at $1.36 billion by end of 2025, North America ~39% of that, and Canada ~17% of North America — described as a >$200 million opportunity. The release also notes SBFM trades as a microcap (market cap under $10 million) and reported a trading-volume surge of +1600% to nearly 10 million shares after the announcement.
Sunshine Biopharma (NASDAQ:SBFM) announced Health Canada approval for Domperidone through its subsidiary Nora Pharma to treat nausea, vomiting and to enhance gastrointestinal motility, including use for chemotherapy-induced nausea.
The approval enables commercialization in Canada and expands Sunshine's generics portfolio. Market data in the release cites global Domperidone sales of $1.36B (2025), North America ~39% share, and Canada ~17% of North America.
Sunshine Biopharma (NASDAQ:SBFM) announced the commercial launch of generic doxycycline in Canada on October 20, 2025, with nationwide availability to pharmacies, hospitals and healthcare providers.
The product is supplied as 100 mg tablets, manufactured in compliance with Health Canada regulatory standards and described as therapeutically equivalent to the reference product. Distribution is underway through established pharmacy networks and hospital channels.
Company commentary ties the launch to its anti-infective expansion and cites a broader North American segment inside a global doxycycline market valued at $729 million in 2024 and forecast to reach $1.2 billion by 2030 (CAGR 8.6%).